Showing 4101-4110 of 6661 results for "".
- Desmoplastic Melanoma May Be Highly Responsive to Anti-PD-1/PD-L1 Therapieshttps://practicaldermatology.com/news/desmoplastic-melanoma-may-be-highly-responsive-to-anti-pd-1pd-l1-therapies/2457926/Patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed, Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature. Pembrolizumab and niv
- BridgeBio Pharma Appoints Drs. Sanuj Ravindran and Eric Michael David as CEOs-in-Residence to Lead Dermatology and Gene Therapy Programshttps://practicaldermatology.com/news/bridgebio-pharma-appoints-drs-sanuj-ravindran-and-eric-michael-david-as-ceos-in-residence-to-lead-dermatology-and-gene-therapy-programs/2457942/BridgeBio Pharma, a clinical-stage biopharmaceutical company, today announced that it has strengthened its executive leadership team with two key hires who will join the company as CEOs-in-residence. Sanuj Ravindran, MD, will serve as CEO of PellePharm, Inc. and wil
- Daily Facial Exercises Help Women to Look Three Years Younger in 20 Weekshttps://practicaldermatology.com/news/daily-facial-exercises-help-women-to-look-three-years-younger-in-20-weeks/2457938/A 30-minute daily or alternate-day facial exercise program sustained over 20 weeks improved the facial appearance of middle-aged women, resulting in a younger appearance with fuller upper and lower cheeks, reports a new Northwestern Medicine study. This is the first scientific study to te
- FDA Approves BMS's Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Diseasehttps://practicaldermatology.com/news/fda-approves-bmss-opdivo-as-adjuvant-therapy-in-patients-with-completely-resected-melanoma-with-lymph-node-involvement-or-metastatic-disease/2457941/The FDA has approved Bristol-Myers Squibb Company's Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The purpose of adjuvant therapy is to reduce t
- BioPhotas, Inc. Launches the Newest Model of the Celluma Serieshttps://practicaldermatology.com/news/biophotas-inc-launches-the-newest-model-of-the-celluma-series/2457943/BioPhotas, Inc. launched its Celluma HOME, a fourth model in the Celluma Series of light therapy devices. The company says the Celluma HOME specifically addresses the challenges of Baby Boomers who struggle with wrinkles, aches and pain. FDA-cleared for over-the-counter purchase, available at an
- NPF Launches New Resource for Youth with Psoriasis, Psoriatic Arthritishttps://practicaldermatology.com/news/npf-launches-new-resource-for-youth-with-psoriasis-psoriatic-arthritis/2457949/Our Spot, a new resource launched by The National Psoriasis Foundation (NPF), provides resources for kids and teens living with psoriasis and psoriatic arthritis. The program includes a
- gel-e Receives US FDA Clearance to Expand its Bandage Product Line for Rx, OTC Usehttps://practicaldermatology.com/news/gel-e-receives-us-fda-clearance-to-expand-its-bandage-product-line-for-rx-otc-use/2457951/The U.S. Food and Drug Administration (FDA) has cleared gel-e Inc.’s adhesive bandage for prescription (Rx) and over-the-counter (OTC) use. This 510(k) clearance expands the Company's label to include the ma
- Study: Minorities Less Likely to See a Doctor for Psoriasishttps://practicaldermatology.com/news/study-minorities-less-likely-to-see-a-doctor-for-psoriasis/2457954/Minorities are less likely than white Americans to see a doctor for psoriasis treatment despite the fact that their disease may be more severe, a new study shows. Researchers from the Perelman School of Medicine at the University of Pennsylvania fou
- Allergan's CoolSculpting Treatment Now FDA Approved to Improve Appearance Of Lax Tissue in Double Chinhttps://practicaldermatology.com/news/allergans-coolsculpting-treatment-now-fda-approved-to-improve-appearance-of-lax-tissue-in-double-chin/2457956/The FDA has approved Allergan plc's CoolSculpting treatment for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments. CoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one tr
- Understanding the Role of Long Strands of RNA in Skin Development, Diseasehttps://practicaldermatology.com/news/understanding-the-role-of-long-strands-of-rna-in-skin-development-disease/2457958/RNA pieces, called “long non-coding RNAs” or “lncRNAs,” help skin cells modulate connective tissue proteins, like collagen, and could represent novel therapeutic targets to promote skin repair, according to researchers from Case Western Reserve University School of Medicin